Skip to content

A randomized, double-blind, placebo-controlled, parallel-group, multi-center clinical trial to assess the effect of Bifidobacterium longum BB536 ingestion on improvement of blood hemoglobin.

A randomized, double-blind, placebo-controlled, parallel-group, multi-center clinical trial to assess the effect of Bifidobacterium longum BB536 ingestion on improvement of blood hemoglobin. - A clinical trial to assess the effect of Bifidobacterium longum BB536 ingestion on hemoglobin improvement.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000019474
Enrollment
60
Registered
2015-10-24
Start date
2015-10-24
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None(Healthy subjects)

Interventions

Sponsors

Tenshi College
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: (1) Women who are more than 18 years old at the time of informed consent acquisition (2) Subjects whose Hb levels are above 12 g/dL and less than 13 g/dL.

Exclusion criteria

Exclusion criteria: (1)Subjects who regularly uses the health foods such as supplements for the purpose of iron or folic acid supply. (2)Subjects who have serious disease (liver, kidney, cerebrovascular, endocrine metabolic diseases, infectious diseases that requires notification) needed to notify (3)Subjects receiving treatment or medication for cancer, and subjects with a history of cancer. (4)Subjects who have a history of major surgery of digestive system (5)Subject with irritable bowel syndrome, inflammatory bowel syndrome or gastrointestinal dysfunction (6)Subject who regularly undertakes medication or treatment that affects bowel motion (such as: antibiotics, antiflatulents, laxatives, antidiarrheal drug) or functional food / nutraceuticals, health supplements (such as: lactic acid bacteria, bifidobacteria, oligosaccharides, dietary fiber) (7)Subject with a history of allergy to medicine and food (8)Subject who donated: 400ml whole blood within past 12 weeks or 200ml whole blood within past 4 weeks or plasma or platelets within past 2 weeks prior to this study (9)Subject who is judged to be ineligible due to subject's background, physical findings, medical examination, physical and clinical examination by principal investigator or sub investigator.

Design outcomes

Primary

MeasureTime frame
Anemia-related indcator(12 weeks after intake)

Countries

Japan

Contacts

Public ContactTaeko Shimoda

Nara Women's University Department of Food and Nutrition

t-shimoda@cc.nara-wu.ac.jp0742-20-3893

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026